Background: Pediatric disruptive behavior disorders (DBDs) are characterized by severe irritability, anger, and temper outbursts. The primary way to treat children with DBDs is parent management training (PMT). PMT teaches parents how to reward desired behaviors and not to reward undesired ones. Researchers want to find out if a smartphone app can help parents apply these skills more effectively. Objective: To test a smartphone app to enhance PMT. Eligibility: Children aged 8 to 13 years with DBDs. A parent or guardian is also needed. Design: Parents will have 12 weekly sessions of PMT. PMT teaches them how to manage their child s mood and behaviors. Parents will learn to actively ignore, praise, set limits, and handle temper outbursts. PMT can be either in person or via video. Sessions last 30 to 60 minutes. They will be video and audio recorded. Parents will be divided into 2 groups. Only 1 group will download a smartphone app. The app helps parents practice PMT skills. It offers videos, a resource library, and alerts when a child may be at risk for various behaviors. All parents will be prompted every day to answer questions about their child s mood and their own behavior. These will continue until 12 weeks after their last PMT session. Children will also answer questions on their phone daily for 1 week at a time. They will do this on 3 different weeks, each about 2 months apart. They will also have check-ins by phone every 2 weeks for up to 6 months. Parents will have follow-up calls 3, 6, and 12 months after they finish PMT.
Study Description: This study is a feasibility study (N=60 parent-child dyads) of a digital tool (machine learning and a smartphone application) augmenting parent management training (PMT) to support the reduction of irritability and temper outbursts through changes in parenting behaviors (i.e., active ignoring) for pediatric disruptive behavior disorders (DBDs). We examine the feasibility of the study design (i.e., two-arm randomized controlled trial \[RCT\] of PMT + ecological momentary assessment \[EMA\] + digital tool vs. PMT + EMA + no digital tool) and examine patterns of change in irritability, outbursts, and parenting behaviors (i.e., active ignoring). Objectives: Primary Objective: Determine the feasibility of the design of a clinical trial (i.e., RCT with two parallel arms - PMT + EMA + digital tool compared to PMT + EMA + no digital tool). Secondary Objective: * Determine whether outbursts and irritability decrease in PMT + EMA + digital tool and PMT + EMA + no digital tool. Determine whether severity of impairment decreases and general functioning improves in both groups. * Determine whether active ignoring increases in PMT + EMA + digital tool and PMT + EMA + no digital tool. Tertiary Objective: * Examine whether attention deficit/hyperactivity disorder (ADHD), anxiety, and depression symptoms decrease in PMT + EMA + digital tool and PMT + EMA + no digital tool. * Monitor treatment acceptability and fidelity and therapeutic support. Endpoints: Primary Endpoint: Dropout in each arm of the trial (PMT + EMA + digital tool vs. PMT + EMA + no digital tool). Secondary Endpoint: * Changes in child outbursts and irritability measured using the Clinician-rated Affective Reactivity Index (CLARI); parent-/child-ARI; Brief Irritability Test (BITe); and parent/child EMA (collected 3x/day from baseline through 3 months post-treatment). Changes in severity of impairment and general functioning using the Children s Global Assessment Scale (CGAS), Clinical Global Impressions Scale-Severity (CGI-S), and Clinical Global Impress Scale-Improvement (CGI-I). * Changes in active ignoring measured using parent EMA (collected 3x/day from baseline through 3 months post-treatment). Tertiary Endpoint: * Changes in symptoms of ADHD, anxiety, and depression. ADHD is measured using the ADHD Rating Scale (ADHD-RS) and Conners Parent Rating Scale (CPRS-R). Anxiety is measured using the Screen for Child Anxiety Related Disorders (SCARED) and Pediatric Anxiety Rating Scale (PARS). Depression is measured using the Mood and Feelings Questionnaire (MFQ) and Child Depression Rating Scale (CDRS). * We will monitor treatment acceptability using the Working Alliance Inventory (WAI) and treatment fidelity using an adherence scale previously developed by our group.
Study Type
OBSERVATIONAL
Enrollment
200
Either parent management training alone or parent management training with a digital tool.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Dropout in each arm of the trial
Differential participant dropout in Group 1 (parent management training + digital tool) compared to Group 2 (parent management training + no digital tool) by parent management training session 12.
Time frame: By parent management training session 12
Clinician Affective Reactivity Index (CL-ARI)
A 12-item clinician-administered measure of temper outbursts, irritable mood, and impairment over the past week, based on parent and child report.
Time frame: Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
Affective Reactivity Index (ARI)
A brief parent- and self-report measure of irritability with 6 core items (score range 0 12) and an additional impairment item not included in the total score.
Time frame: Pre-treatment, weekly during treatment, mid-treatment, post-treatment
Brief Irritability Test (BITe)
A 5-item self-report measure assessing irritability over the past two weeks on a 6-point scale.
Time frame: Pre-treatment, mid-treatment, post-treatment
Clinical Global Impressions Improvement (CGI-I)
A clinician-rated, diagnosis-independent measure of overall treatment response, assessing change from relative to a baseline on a 7-point scale (1 = very much improved to 7 = very much worse).
Time frame: Pre-treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
Clinical Global Impressions Severity (CGI-S)
A clinician-rated measure of the patient s current level of psychopathology on a 7-point Likert scale ranging from 1 (Normal, not at all ill) to 7 (Among the most extremely ill patients), providing a single global index of illness severity at the time of assessment.
Time frame: Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
The Children s Global Assessment Scale (CGAS)
A clinician rated, diagnosis nonspecific measure of overall functioning in children and adolescents. It provides a single global rating of the child s psychological, social, and school functioning over a specified time period (usually the current level or past week), based on all available clinical information. Scored on a 100 point continuum divided into 10 point descriptive anchor ranges, with scores ranging from 1 (most impaired functioning) to 100 (superior functioning). Higher scores indicate better overall functioning, while lower scores reflect increasing levels of impairment.
Time frame: Pre-treatment, bi-weekly during treatment, mid-treatment, post-treatment, follow up (3-, 6-, and 12-months)
Ecological momentary assessment (EMA) of child temper outbursts and irritability
EMA items are parent-report and child-report of child temper outbursts and irritability.
Time frame: In both groups, parents/guardians complete EMA 3x/day from a baseline period through 12 weeks post-treatment (up to 30 weeks) and children complete EMA 3x/day for one week pre-, mid-, and post-treatment (3 weeks total)
Ecological momentary assessment (EMA) of parent active ignoring
EMA items are parent-report of parent use of the active ignoring skill.
Time frame: In both groups, parents/guardians complete EMA 3x/day from a baseline period through 12 weeks post-treatment (up to 30 weeks)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.